Completed PHASE2 INTERVENTIONAL 6-arm NCT03336593

Protectivity and Safety of Quadrivalent Influenza HA Vaccine in Indonesian Population

A Bridging Study to Assess Protectivity and Safety of Quadrivalent Influenza HA Vaccine in Indonesian Population

Sponsor: PT Bio Farma

Interventions Quadrivalent Influenza Vaccine Trivalent Influenza Vaccine

Updated 7 times since 2017 Last updated: Apr 1, 2019 Started: Nov 21, 2017 Primary completion: Mar 14, 2018 Completion: Nov 30, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03336593, this PHASE2 trial focuses on Safety Issues and remains completed. Sponsored by PT Bio Farma, it has been updated 7 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
May 2019 — Jan 2021 [monthly]

Completed PHASE2

Status: Recruiting → Completed
Jun 2018 — May 2019 [monthly]

Recruiting PHASE2

▶ Show 2 earlier versions

Mar 2018 — Jun 2018 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Dec 2017 — Mar 2018 [monthly]

Not Yet Recruiting PHASE2

First recorded

Nov 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

PT Bio Farma

Data source: PT Bio Farma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bandung, Indonesia